Please do not leave this page until complete. This can take a few moments.
An investigational drug from New Haven’s BioXcel Therapeutics showed strong results in reducing the agitation associated with bipolar disorder, the company reported Tuesday.
The drug, BXCL501 (sublingual dexmedetomidine), significantly reduced agitation at doses of 120 mcg and 180 mcg compared with a placebo, according to study results.
BXCL501 is administered in an orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2 receptor agonist for the treatment of agitation associated with neuropsychiatric disorders, the company said in a statement.
The Phase 3 trial results were reported in the Journal of the American Medical Association.
The BioXcel drug shows promise as a noninvasive and patient-administered treatment for agitation, said the study’s author, Dr. Sheldon H. Preskorn of the University of Kansas School of Medicine-Wichita.
“This research is an important milestone in the development of a patient-centric treatment approach for agitation – a difficult-to-manage symptom associated with many psychiatric and medical conditions,” Preskorn said.
Agitation presents as a common symptom of neuropsychiatric conditions including bipolar disorders I and II and schizophrenia, which are diagnosed in an estimated 7.3 million people in the U.S.
“A non-invasive therapy that causes rapid and sustained symptom relief may be helpful to avoid the costly and traumatic use of coercive techniques, like physical restraint and seclusion, which may result in admission and prolonged hospitalization,” according to a BioXcel statement.
Another BioXcel investigational drug, BXCL701, showed good results in a study in patients with a rare and aggressive form of prostate cancer, the company reported earlier this month.
Contact Liese Klein at lklein@newhavenbiz.com.
This special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThis special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments